search
Guardant Health
Trends
- 1WGS Oncodetect beats WES version in colorectal cancer recurrence detection▼WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer, company reports
Guardant Health reports that its whole-genome sequencing version of the Oncodetect molecular residual disease test detected cancer recurrence with higher sensitivity than the whole-exome sequencing version in colorectal cancer. The company says the findings support the WGS-based assay's ability to identify minimal residual disease earlier, which could matter for monitoring patients after treatment and guiding follow-up decisions in colorectal cancer care.